C12Y 114/99003
Heme oxygenase
Official title: Heme oxygenase (1.14.99.3)
C12Y114/99003 (Heme oxygenase) appears on 16 US grants and 34 published applications in this corpus.
Search patents in C12Y- Granted patents
- 16
- Published applications
- 34
- Assignees
- 24
- Inventors
- 80
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 2 |
| 2011 | 0 | 2 |
| 2012 | 1 | 1 |
| 2013 | 2 | 0 |
| 2014 | 0 | 4 |
| 2015 | 1 | 3 |
| 2016 | 0 | 0 |
| 2017 | 1 | 0 |
| 2018 | 1 | 1 |
| 2019 | 1 | 3 |
| 2020 | 2 | 3 |
| 2021 | 1 | 2 |
| 2022 | 0 | 0 |
| 2023 | 0 | 2 |
| 2024 | 1 | 1 |
| 2025 | 1 | 2 |
| 2026 | 3 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cardiac-specific targeting-peptide (CTP), compositions, and uses thereof2 Jun 2026US 12,643,924 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance26 May 2026US 12,637,690 B2eGenesis, Inc.
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance19 May 2026US 12,630,838 B2eGenesis, Inc.
- Glycated hemoglobin oxidase variant and method for measurement25 Mar 2025US 12,258,589 B2Kikkoman Corporation
- Cell model for in vitro evaluation of compound-induced skin sensitization and a constructing method therefor24 Dec 2024US 12,173,283 B2South China University of Technology
- Compositions and methods for treating pulmonary conditions6 Aug 2026US 2026/0224499 A1Mayo Foundation for Medical Education and Research
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance9 Apr 2026US 2026/0098278 A1eGenesis, Inc.
- A genetically modified yeast cell for hemoglobins production25 Dec 2025US 2025/0388852 A1Chrysea Limited
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance13 Nov 2025US 2025/0346918 A1eGenesis, Inc.
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance14 Mar 2024US 2024/0084322 A1eGenesis, Inc.
Most cited
By later US patents
- Inhibition of smooth muscle cell migration by heme oxygenase I24US 6,203,991 B1The Regents of the University of Michigan · 2001
- Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation4US 8,097,585 B2Beth Israel Deaconess Medical Center, Inc. · 2012
- Biliverdin from a non-animal source3US 8,455,222 B2Utah State University · 2013
- Diagnosis and treatment of preeclampsia3US 8,568,999 B2A1M Pharma AB · 2013
- Lipocalin fusion partners2US 10,156,559 B2Fred Hutchinson Cancer Research Center · 2018